Tianjin Lisheng Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Tianjin Lisheng Pharmaceutical Co., Ltd. (securities code 002393) was founded in 1951 and is a pharmaceutical enterprise that has grown with the pace of industrial revitalization in New China. For decades, the company has been widely praised by society for producing high-quality drugs to serve human health, and has made positive contributions to China's pharmaceutical and health industry. The company currently has two wholly-owned subsidiaries: Tianjin Central Pharmaceutical Co., Ltd. (hereinafter referred to as "Central Pharmaceutical") and Tianjin Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as "Biochemical Pharmaceutical"). We have four participating companies: Tianjin Pharmaceutical Group Finance Co., Ltd., Tianjin Tianbian Pharmaceutical Co., Ltd., Tianjin Ledun Traditional Chinese Medicine Co., Ltd., and Tianjin Pharmaceutical Group Marketing Management Co., Ltd. The wholly-owned subsidiary, Central Pharmaceutical, has a stake in Tianshili Holding Group Co., Ltd. The company has been recognized as a national high-tech enterprise and a national green factory. The product covers 15 major categories, with a total of 243 drug approval numbers, involving traditional Chinese and Western medicine tablets, capsules, oral liquids, granules, biological preparations, and raw materials. We have multiple "Chinese Famous Trademarks" and "Tianjin Famous Trademarks". The marketing network covers the whole country, and some products are exported to various parts of the world. Among them, core products such as "Shoubishan" brand indapamide tablets, "Xifuni" brand cefdinib dispersible tablets, Maren soft capsules, and nadroparin calcium injection have gained high market recognition. Lisheng people always adhere to the business philosophy of "being a good person and doing a good job in medicine", focus on continuous innovation in important treatment fields such as cardio cerebrovascular, anesthesia and analgesia, mental, anti infection, anti diabetes, and tonics, and constantly improve the quality of human life. In the future, the company will firmly focus on the development path of high-quality innovation and upgrading of its main business, maintain strategic focus, strengthen development confidence, set goals without relaxation, forge ahead, and move towards the development goal of an advanced pharmaceutical enterprise with core competitiveness, industry influence, and international capabilities, making Lisheng Company an excellent pharmaceutical enterprise worthy of patient trust. |
| Headquarter | Tianjin |
| Establish Date | 6/17/1981 |
| Listed Code | 002393.SZ |
| Listed Date | 4/23/2010 |
| Chairman | Zhang Ping. |
| CEO | Wang Fujun. |
| Website | www.lishengpharma.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
